The Materials Research Society Fall Meeting & Exhibit is a premier international event for materials research professionals to discuss the latest advancements and innovations. It is ideal for scientists, engineers, and industry leaders from around the globe.
The Materials Research Society Fall Meeting & Exhibit is a significant event in the field of materials research, bringing together experts from academia, industry, and government. Attendees can expect a vibrant exchange of ideas and insights into current scientific challenges and technological innovations. Through a diverse range of sessions, including poster sessions, technical symposia, and exhibit opportunities, the event promotes collaboration and networking among participants. Attendees will leave equipped with the latest knowledge and resources to advance their work in…
What you will learn
Discover the latest advancements in materials research.
Network with international professionals in the field.
Explore cutting-edge innovations and technologies.
Participate in interdisciplinary sessions and workshops.
Gain insights from leading experts and keynote speakers.
Want to exhibit at this event?
MarketScale can act as a third-party concierge, helping you request exhibitor packages, pricing, and booth availability. No cold calls, no commitment.
Key Highlights
• Presentations from renowned materials scientists.
• Innovative technologies in materials research.
• Interdisciplinary panel discussions.
• Workshops on emerging materials engineering trends.
Frequently asked questions
Topics & tracks
MarketScale platform
Exhibiting at this event?
Capture customer testimonials onsite, with your iPhone.
MarketScale turns every booth conversation into a produced video clip, written article, and social posts. No crew. No editing. Done before you land home.
Learn how →sciences articles
Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade
More than $300 billion in branded pharmaceutical revenue faces patent expiration by 2030. Big Pharma cannot replace it through internal R&D alone. The result is the most aggressive acquisition cycle since before the pandemic, and it is reshaping how the entire life sciences supply chain does business.
Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic
Quotient Sciences initiates what it calls the first Phase I trial of an AI-designed oral drug formulation, approved by the UK's MHRA.
Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic
Quotient Sciences has initiated a Phase I study of an AI-designed oral formulation, cleared by the MHRA—marking a concrete shift from AI experimentation to clin
MarketScale
MarketScale helps B2B teams cover events like this and turn them into content their market reads. Want to talk through what that looks like?